The Life Sciences Investment Programme (LSIP) is a £200m initiative managed by British Patient Capital designed to address the growth equity finance gap faced by high-potential UK life sciences companies. This is expected to attract at least a further £400m of private investment.
Through LSIP, we make cornerstone commitments to later stage life sciences venture growth funds with a strong UK focus, typically investing between £50m and £100m in each successful fund.
Dedicated life sciences focus
Funds providing later-stage capital
UK presence in investment team
Minimum target fund size of £250m
Focus on funding UK companies
Find out more
For further information please see our Request for Proposals.
Unfortunately this site does not support your browser
This site may not display correctly in your current browser. To view the site in its intended form and for the best user experience, download the latest version of your browser using the options below.